A genome-wide association meta-analysis on apolipoprotein A-IV concentrations. by Lamina, C. et al.
A S S O C I A T I O N S T U D I E S A R T I C L E
A genome-wide association meta-analysis on
apolipoprotein A-IV concentrations
Claudia Lamina1,†, Salome Friedel1,†, Stefan Coassin1, Rico Rueedi3,4,
Noha A. Yousri5,6, Ilkka Sepp€al€a7, Christian Gieger8,9,10,
Sebastian Scho¨nherr1, Lukas Forer1, Gertraud Erhart1, Barbara Kollerits1,
Pedro Marques-Vidal11, Janina Ried8, Gerard Waeber11, Sven Bergmann3,4,
Doreen D€ahnhardt1, Andrea Sto¨ckl1, Stefan Kiechl2, Olli T. Raitakari12,13,
Mika K€aho¨nen14, Johann Willeit2, Ludmilla Kedenko15,
Bernhard Paulweber15, Annette Peters9,16,17, Thomas Meitinger18,19,20,
Konstantin Strauch8,21, KORA Study Group, Terho Lehtim€aki7,
Steven C. Hunt22,23, Peter Vollenweider11 and Florian Kronenberg1,*
1Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology,
Medical University of Innsbruck, Innsbruck, Austria, 2Department of Neurology, Medical University of
Innsbruck, Innsbruck, Austria, 3Department of Computational Biology, University of Lausanne, Lausanne,
Switzerland, 4Swiss Institute of Bioinformatics, Lausanne, Switzerland, 5Department of Physiology and
Biophysics, Weill Cornell Medical College  Qatar, Doha, Qatar, 6Department of Computer and Systems
Engineering, Alexandria University, Alexandria, Egypt, 7Department of Clinical Chemistry, Fimlab Laboratories
and University of Tampere School of Medicine, Tampere, Finland, 8Institute of Genetic Epidemiology,
Helmholtz Zentrum Mu¨nchen—German Research Center for Environmental Health, 9Institute of Epidemiology
II, Helmholtz Zentrum Mu¨nchen—German Research Center for Environmental Health, 10Research Unit of
Molecular Epidemiology, Helmholtz Zentrum Mu¨nchen—German Research Center for Environmental Health,
Neuherberg, Germany, 11Department of Medicine, Internal Medicine, Centre Hospitalier Universitaire Vaudois
(CHUV), Lausanne, Switzerland, 12Department of Clinical Physiology, Turku University Hospital, Turku,
Finland, 13Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku,
Finland, 14Department of Clinical Physiology, Tampere University Hospital and University of Tampere,
Tampere, Finland, 15First Department of Internal Medicine, Paracelsus Private Medical University, Salzburg,
Austria, 16DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich,
Germany, 17German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany, 18Institute of Human
Genetics, Technische Universit€at Mu¨nchen, Mu¨nchen, Germany, 19Institute of Human Genetics, Helmholtz
Zentrum Mu¨nchen, Neuherberg, Germany, 20Munich Cluster for Systems Neurology (SyNergy), 21Institute of
Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-
†The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
Received: May 4, 2016. Revised: June 20, 2016. Accepted: June 27, 2016
VC The Author 2016. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
3635
Human Molecular Genetics, 2016, Vol. 25, No. 16 3635–3646
doi: 10.1093/hmg/ddw211
Advance Access Publication Date: 12 July 2016
Association Studies Article
Universit€at, Munich, Germany, 22Cardiovascular Genetics Division, University of Utah School of Medicine, Salt
Lake City, UT, USA and 23Department of Genetic Medicine, Weill Cornell Medicine, Doha, Qatar
*To whom correspondence should be addressed at: Florian Kronenberg, MD, Division of Genetic Epidemiology, Department of Medical Genetics, Molecular
and Clinical Pharmacology, Innsbruck Medical University, Scho¨pfstr. 41, A-6020 Innsbruck, Austria. Tel: þ43 512 9003-70560; Fax: þ43 512 9003-73560 or -
73561; Email: Florian.Kronenberg@i-med.ac.at
Abstract
Apolipoprotein A-IV (apoA-IV) is a major component of HDL and chylomicron particles and is involved in reverse cholesterol
transport. It is an early marker of impaired renal function. We aimed to identify genetic loci associated with apoA-IV concen-
trations and to investigate relationships with known susceptibility loci for kidney function and lipids. A genome-wide associ-
ation meta-analysis on apoA-IV concentrations was conducted in five population-based cohorts (n¼13,813) followed by two
additional replication studies (n¼2,267) including approximately 10 M SNPs. Three independent SNPs from two genomic re-
gions were significantly associated with apoA-IV concentrations: rs1729407 near APOA4 (P¼6.7710 44), rs5104 in APOA4
(P¼1.791024) and rs4241819 in KLKB1 (P¼5.61014). Additionally, a look-up of the replicated SNPs in downloadable
GWAS meta-analysis results was performed on kidney function (defined by eGFR), HDL-cholesterol and triglycerides. From
these three SNPs mentioned above, only rs1729407 showed an association with HDL-cholesterol (P¼7.110 07). Moreover,
weighted SNP-scores were built involving known susceptibility loci for the aforementioned traits (53, 70 and 38 SNPs, respec-
tively) and were associated with apoA-IV concentrations. This analysis revealed a significant and an inverse association for
kidney function with apoA-IV concentrations (P¼5.51005). Furthermore, an increase of triglyceride-increasing alleles was
found to decrease apoA-IV concentrations (P¼0.0078). In summary, we identified two independent SNPs located in or next
the APOA4 gene and one SNP in KLKB1. The association of KLKB1 with apoA-IV suggests an involvement of apoA-IV in renal
metabolism and/or an interaction within HDL particles. Analyses of SNP-scores indicate potential causal effects of kidney
function and by lesser extent triglycerides on apoA-IV concentrations.
Introduction
Apolipoprotein A-IV (apoA-IV) is an antioxidative glycoprotein that
is synthesized primarily in the intestine and to a lesser extent in
the liver (1,2). It is secreted into the lymph as a structural protein of
chylomicrons, very-low-density lipoproteins, high-density lipopro-
teins and participates in reverse cholesterol transport (3,4).
Consequently, it plays an important role in relieving peripheral
cells of an overload of cholesterol (5,6). It has an effect on fat re-
sorption and has been discussed to be a satiety factor and related
to diet-induced obesity at least in animal models (2). ApoA-IV
shows anti-atherogenic properties (7,8) and low concentrations
were found to be associated with cardiovascular outcomes (9–12).
Moreover, it acts as an early marker of impaired renal function and
is a predictor of a progression of chronic kidney disease (13–16).
The knowledge on the genetic regulation of apoA-IV is lim-
ited. Heritability estimates derived from a family-based study in
119 nuclear families varied between 0% and 67%, depending on
the underlying model (17). ApoA-IV is expressed by the APOA4
gene on chromosome 11. This gene is in close proximity and
linkage with APOA5, APOC3 and APOA1. This gene region is of-
ten referred as the APOA5-A4-C3-A1 gene cluster. There have
been numerous candidate gene studies, which primarily evalu-
ated the non-synonymous variants rs675 (T347S) and rs5110
(Q360H) with e.g. the ability of apoA-IV to bind lipids and to pro-
mote cholesterol efflux from cells (18). Association results of
these variants with plasma apoA-IV levels (19,20) as well pro-
posed associations with triglycerides were contradictory (21–
23). Variants in the APOA5-A4-C3-A1 gene cluster have also
been found to be associated on a genome-wide scale with lipid
phenotypes, primarily with triglyceride and HDL cholesterol
(HDL-C) concentrations (24). Up to now, there have been no
genome-wide studies (GWAS) investigating apoA-IV
concentrations.
The aim of the present study was to identify gene loci that
are associated with apoA-IV concentrations based on a
hypothesis-free approach. We conducted a genome-wide asso-
ciation meta-analysis using data from five population-based
studies followed by a replication step in two additional studies.
We also performed gene-based and pathway analyses to shed
new light on the functional role of the identified genes and/or
apoA-IV. Since the information on the heritability of apoA-IV is
limited, we conducted a polygenic analysis to calculate the heri-
tability of apoA-IV concentrations as well as the proportion of
phenotypic variance explained by the single nucleotide poly-
morphisms (SNPs). ApoA-IV is known to be associated with kid-
ney function and lipid phenotypes. Therefore, we also
performed look-ups in and from the respective GWAS to eluci-
date possible causal relationships.
Results
Description of cohorts and quality control
Five studies contributed to the discovery stage (n¼ 13,813) and 2
additional studies to the replication phase (n¼ 2,267) (Figure 1),
altogether including data from 16,080 participants. Due to the
skewed distribution of apoA-IV concentrations, log-
transformation of values was performed in all studies, resulting
in nearly normal distributions (Supplementary Material, Figure
1). Descriptive characteristics of all studies can be found in
Supplementary Material, Table 1. Meta-Analysis and quality
control was performed as described in Supplementary Material,
Figure 2. The P-Z-plot did not reveal any deviations of the re-
ported P-values and P-values calculated by the beta coefficient
and standard error. Genomic inflation factors k within studies
ranged from 1.011 to 1.038 (Supplementary Material, Table 2).
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GWA discovery stage
The GWA meta-analysis (stage 1) resulted in two genome-wide
significant gene-regions (Manhattan plot shown in Figure 2,
QQ-plot shown in Supplementary Material, Figure 3). In a
broad region surrounding the APOA4 gene, 423 SNPs reached
genome-wide significance with the lowest P-value for SNP
rs1729407 (P¼ 6.001040, Figure 3). Additionally, 64 genome-
wide significant SNPs in the gene-region around the KLKB1
gene on chromosome 4 were identified (lowest P-value for SNP
rs4241819: 1.081012, Figure 4). Furthermore, one locus on
chromosome 5 (SOWAHA) reached our predefined level of sig-
nificance sufficient for replication using the RE model by Han
& Eskin (lowest P-value for SNP rs59698941: 3.761007,
Supplementary Figure 4).
SNP selection
Conditional analyses were performed for APOA4 (chr11:
116177370-117177370, Figure 3), KLKB1 (chr4: 186657140-
187657140, Figure 4) and SOWAHA (chr5: 131654912-132654912,
Supplementary Material, Figure 4). For APOA4, two SNPs were
independently associated with apoA-IV concentrations: rs1729407
(P-value single SNP analysis: 6.00 1040; P-value conditional
analysis: 2.66 1025) and rs5104 (P-value single SNP analysis:
1.24 1022; P-value conditional analysis: 4.01 1008,
Supplementary Material, Figure 5) . After apoA-IV concentrations
were adjusted for these two SNPs, no further SNPs remained in the
model with an adjusted P-value less than 1x106 (Supplementary
Material, Figure 6). Besides the two SNPs rs1729407 and rs5104 the
following missense variants were selected for replication: rs5110
(P¼ 9.26 10 07) and rs675 (P¼ 0.0021). The latter was selected
due to its wide use in the literature. For KLKB1 and SOWAHA, no
additional SNP was added by applying the conditional analysis.
One missense variant was selected within the SOWAHA gene re-
gion (rs2292030, P¼ 9.24 1007 using the RE model, within
SHROOM1). The lead SNP in KLKB1 (rs4241819) and the KLKB1 mis-
sense variant rs3733402 that were selected for replication were not
accessible to iPLEX genotyping. Therefore, a proxy SNP (rs4253311)
in high linkage disequilibrium (LD) with both the lead SNP and the
missense variant was chosen for replication (P¼ 1.43 1011,
r2¼0.932 with rs4241819, r2¼0.994 with rs3733402, based on 1000
Genomes phase 3 v5; see also Figure 4 for graphical display of LD
between the SNPs). Characteristics of all selected SNPs can be
found in Supplementary Material, Table 3.
Replication stage and combined analysis
Altogether, 7 SNPs were genotyped in the two replication studies.
The single study results for these SNPs are given in
Supplementary Material, Table 4. Of these, 3 SNPs reached a false-
discovery rate less than 0.05 on the replication stage and a
genome-wide significance level after inclusion of all 7 studies (dis-
covery stageþ replication stage, Table 1): rs1729407 near APOA4
(P¼ 6.77 1044), rs5104 in APOA4 (P¼ 1.79 1024) and rs4241819
(using rs4253311 as proxy in the replication studies) in KLKB1
(P¼ 5.631014). For these 3 SNPs, effect directions were identical
in all studies. For each copy of the minor allele of rs1729407, apoA-
IV concentrations decrease by 0.2645 mg/dl. Each minor allele of
rs5104 also decreases apoA-IV concentrations by 0.2526 mg/dl. In a
joint analysis, both SNPs remain significant (P¼ 2.66 1025 for
rs1729407, P¼ 4.01 1008 for rs5104) with slightly smaller effect
GWA discovery stage stage
CoLaus (n = 3,996)
FamHS (n = 1,712)
KORAF3 (n = 3,075)
KORAF4 (n = 2,926)
Young Finns Study (n = 2,104)
Replication stage
Total: n = 13,813
Independent SNPs & 
missense variants with 
p < 1x10-6 
Bruneck (n = 802)
SAPHIR (n = 1,465)
Total GWAS + Replicaon: n = 16,080
“Replicaon”: p < 5x10-8 in combined 
analysis & direcon of eﬀects consistent 
to GWAS in replicaon studies
Figure 1. Overview of contributing cohorts in the discovery and replication
stage.
Figure 2. Manhattan-plot for the meta-analysis on log-transformed apoA-IV values. Results are based on five discovery cohorts including 13813 individuals.
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estimates (b¼ 0.2041 for rs1729407 and b¼ 0.1455 for rs5104). The
minor allele of SNP rs4241819/rs4253311 in KLKB1 increases apoA-
IV concentrations by 0.1469 mg/dl.
Effects in men and women
GWAS stratified for men and women did not reveal any addi-
tional genome-wide significant SNPs outside the wider APOA4
gene region (Supplementary Material, Figures 7 and 8). There
was also no genome-wide significant SNP-gender interaction ef-
fect (Supplementary Material, Figure 9).
APOA-IV variance explained
All SNPs combined within the broad APOA4 region (lead SNPþ/-
500 kB) explained 3.30% (95% CI: [1.60%; 5.00%]) of the
Figure 3. Regional plot showing the genomic region defined by the APOA4-lead SNP rs1729407þ/- 500 kB (LD refers to rs1729407, based on 1000G EUR); P-values are
derived from the meta-analysis on the five discovery cohorts on log-transformed apoA-IV concentrations.
Figure 4. Regional plot showing the genomic region defined by the KLKB1-lead SNP rs4241819þ/- 500 kB (LD is based on 1000G EUR and refers to rs4253311 which was
used as a proxy for the lead SNP in the replication studies); additionally, the missense variant rs3733402 is marked. P-values are derived from the meta-analysis on the
five discovery cohorts on log-transformed apoA-IV concentrations.
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phenotypic variance assuming an additive model, based on
both KORA studies. The top SNP rs1729407 alone explained
1.38% in KORAF3/F4 and 1.39% in the SAPHIR study, respec-
tively, and rs5104 alone 1% in KORAF3/F4 and 0.57% in SAPHIR.
The KLKB1 region (lead SNPþ/- 500 kB) accounted for 0.67% (95%
CI: [0.00%; 1.54%]) in KORAF3/F4. SNP rs4241819/rs4253311 alone
explained 0.44% in KORAF3/F4 and 0.19% in the SAPHIR study,
respectively. All three SNPs together (two in APOA4, one in
KLKB1) in one model explained 2.2% in the combined KORAF3/
F4 dataset. The genome-wide SNP-based explained variance in-
cluding the entire dataset of available SNPs (genomic heritabil-
ity) was estimated to be 36.07% in both KORA studies (95% CI:
[18.48%; 53.66%]). The narrow-sense heritability h2 of apoA-IV,
derived from the polygenic model in the family-based FamHS
study, was estimated to be 27.45%.
Gene-based and pathway analyses
The gene-based association scan resulted in 18 significant
genes, all of which are located either in the broad APOA4 or
KLKB1 gene regions (Table 2). The pathway analysis revealed 15
gene sets to be significantly enriched with susceptibility genes,
including expected lipid transport and lipoprotein metabolism
pathways as well as some additional liver-related pathways
(Supplementary Material, Table 5).
Look-up in other GWAmeta-analysis consortia
We looked up the two replicated SNPs in the APOA4 gene region
(rs1729407, rs5104), the replicated SNP in KLKB1 (rs4241819), its
proxy used in the replication step (rs4253311) and the correlated
missense mutation (rs3733402) in the GWA meta-analysis re-
sults on kidney function, HDL-C and triglycerides. Two SNPs
(rs1729407, rs4253311) were available in all GWAS consortia.
Only one significant result was found: the apoA-IV lead SNP
rs1729407 was associated with HDL-C with a P-value of
7.110 07 (Table 3).
In addition, lead SNPs from the most recent HDL-C (n¼ 70), tri-
glyceride (n¼ 38) and kidney function (n¼ 53) GWAS were se-
lected. The P-values of these partially overlapping 142 SNPs were
retrieved from our GWA meta-analysis on log-transformed apoA-
IV (Supplementary Material, Tables 6–8). Only one SNP was signif-
icantly associated with apoA-IV, rs964184 in APOA1 (P¼ 0.0001),
which is included in the HDL-C as well as in the triglyceride SNP
list.
The analyses based on the weighted genetic SNP-scores for
kidney function, HDL-C and triglycerides in the combined KORA
F3 and F4 dataset yielded two significant results. The weighted
kidney function SNP-score was significantly and inversely
associated with apoA-IV (P¼ 5.51005). That means apoA-IV
concentrations increased with an increasing number of
GFR-decreasing SNPs. Furthermore, a greater number of
triglyceride-increasing alleles was shown to be associated with
lower apoA-IV concentrations (P¼ 0.0078). The association with
HDL-C SNPs was not significant but pointed in the opposite di-
rection as expected: the more HDL-C-increasing alleles, the
higher were apoA-IV concentrations (P¼ 0.0554).
Discussion
This study revealed three major findings. First, using genome-
wide data from five studies and two independent replication
studies we could identify three independent SNPs from two geno-
mic regions (APOA4 and KLKB1), which were significantly associ-
ated with apoA-IV concentrations. Second, approximately one
third of the phenotypic variability of apoA-IV seems to be geneti-
cally regulated. Third, genetic variants that have a significant ef-
fect on kidney function and triglyceride concentrations suggest a
causal role of these phenotypes on apoA-IV concentrations.
Genome-wide significant and replicated SNPs in APOA4
and KLKB1
Conditional stepwise regression analysis including all SNPs in
the broad APOA4 gene region (a 1 MB region including the
Table 1. Meta-analysis results of selected SNPs for replication (P-value< 1E-06 in the GWAs stage); the beta estimate and effect direction refer
to the minor allele
GWAS stage Replication stage GWAS 6 Replication
SNP b (se)* Effect
Direction§
P I2 b (se)* Effect
Direction§
p/FDR$ b (se)* p I2
APOA4 gene region
rs1729407 0.2459 (0.0289)  6.00E-40 0 0.4895 (0.1003)  3.73E-06/2.59E-05 0.2645 (0.0277) 6.77E-44 25.34
rs5104 0.2399 (0.0367)  1.24E-22 15.630.4533 (0.1460)  0.0013/0.0046 0.2526 (0.0356) 1.79E-24 11.05
rs5110 0.2301 (0.0774) þþþþþ 9.26E-07 0 0.0520 (0.1956)  þ 0.9124/0.9124 0.2060 (0.0720) 1.44E-05 1.37
APOA4 gene region, selected from literature
rs675 0.1041 (0.0380)  0.0021 0 0.1462 (0.1183)  0.2931/0.5129 0.1081 (0.0362) 0.0013 0
Other gene regions
KLKB1: rs4241819/rs4253311 0.1395 (0.0280) þþþþþ 1.08E-12 45.89 0.2410 (0.1006) þþ 0.0093/0.0217 0.1469 (0.0270) 5.63E-14 36.03
SOWAHA: rs59698941 0.3542 (0.1420)#  3.76E-07& 68.830.0162 (0.1638)#þ 0.6637&/0.7743 0.2628 (0.1111) # 1.75E-06& 64.86
SHROOM1: rs2292030 0.3502 (0.1407)#  9.24E-07& 66.330.0222 (0.1491)#þ 0.6584&/0.7743 0.2629 (0.1090)# 4.28E-06& 59.86
*All effect estimates (b and se) are based on the original scale of apoA-IV, either fixed effect or random effect. Where labeled, all effect estimates refer to the minor allele
derived from 1000G, phase 3v5 (see Supplementary Material, Table 3).
§Order of included GWA studies: CoLaus, FamHS, KORA F3, KORA F4, YFS.þ: positive effect from minor allele on log(apoA-IV) in that specific study,: inverse effect
from minor allele on log(apoA-IV) in that specific study;?: SNP not available in that study; Order of included studies at replication stages: Bruneck, SAPHIR.
&P-values are derived from the method proposed by Han and Eskin.
#Random effects b and se.
$False-discovery rate by Benjamini and Hochberg (50).
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APOA5-A4-C3-A1 cluster) led to the identification of two SNPs:
the lead SNP rs1729407, located between APOA5 and APOA4,
and one missense variant (rs5104). So far, the effect of rs5104
has been studied only in some small studies: it was associated
with dyslipidemia in Han Chinese (25), with postprandial ApoA-
I plasma concentration in healthy young men (26) and with tri-
glyceride response to fenofibrate treatment (27). Conversely, no
association between the lead SNP rs1729407 and any phenotype
had been shown until now. The effect of other missense vari-
ants in APOA4 (rs675, rs5110), although widely studied before,
could not be replicated. However, these previous studies were
markedly smaller, showed contradictory results and investi-
gated different inheritance models (19,20,23).
Both APOA4 top hits do not present overt functional effects.
The lead SNP rs1729407 is located in an intergenic region
(Supplementary Material, Figure 10A) while rs5104 causes a ser-
ine to asparagine substitution (Ser147Asn), which is classified
as benign by common bioinformatics prediction tools. Of note,
the lead SNP is in perfect LD (r2¼1) with a SNP located in a large
cluster of transcription factor binding sites located approxi-
mately 1.5 kb downstream (rs1729405, P¼ 9.92E-40 in our meta-
analysis; Supplementary Material, Figure 10B).
Besides the APOA4 gene, we also identified a locus on chro-
mosome 4 encompassing the three genes CYP4V2, KLKB1 and
F11. The top hit was in nearly perfect LD with the missense vari-
ant rs3733402 in KLKB1. KLKB1 encodes the glycoprotein plasma
kallikrein (also known “Fletcher factor” (28)), which acts as a
proteolytic activator of several vasoactive and circulating pep-
tides (kinins) (29,30). Accordingly, SNPs in KLKB1 showed
genome-wide associations with vasoactive peptides (plasma
bradykinin (31,32), active renin (rs3733402) (33), BNP in Blacks
(34), aldosterone/renin ratio in Europeans (34), MR-pro-ADM
and CT-pro-ET-1 (rs4253238 (35), r2¼0.81 with our tophit). Of
note, F11 is a paralog of KLKB1 and codes for the coagulation fac-
tor XI. Both are part of the intrinsic pathway (36). However, to
our knowledge a mechanism which obviously links apoA-IV to
the kinin-kallikrein system or the intrinsic pathway has not
been described so far. Therefore, replication and functional
studies will be required to appraise the significance of this find-
ing. The third gene in the locus, CYP4V2, is a nearly ubiquitously
expressed omega-hydroxylase, with the phenotype of loss-of-
function mutations being restricted to the eye (37,38) and caus-
ing the degenerative ocular disease BCD (39) (OMIM #210370).
Finally, gene-based analysis or pathway-based analysis did
not reveal additional novel genes beyond those located in the
genomic regions around APOA4 and KLKB1. Since the stepwise
conditional analysis resulted in only two independent SNPs
located at the APOA4 or KLKB1 loci, the observation in the gene-
based analysis that multiple genes were significant in each lo-
cus could most likely be explained by LD.
Variance explained and heritability
Another aim of this study was the estimation of the heritability
of apoA-IV as well as the variation of apoA-IV explained by all
included additive-coded SNPs. Both, genomic and also narrow-
sense heritability were calculated to be around 30%. Only a rela-
tively small fraction is explained by the two gene regions we
have identified which leaves sufficient room for the discovery of
other gene regions. In addition, the major extent of apoA-IV
concentrations seems to be regulated by non-genetic factors.
SNP look-up using results from other GWAS consortia
Another aspect of this study was the look-up of the identified
SNPs in other GWAS consortia. Since variants in the APOA5-A4-
C3-A1 gene cluster have consistently been found to be associ-
ated with triglycerides and HDL-C (24,40,41), results from the
most recent lipids-GWA meta-analysis (24) was used for this
look-up. The lead APOA4-SNP rs1729407 showed an association
Table 2. Results of gene-based analysis
Gene Nominal P-value Bonferroni-corrected P-value Chromosome Position Group
ZPR1 7.93E-39 1.9E-34 11 116649275 protein-coding gene
APOA5 2.14E-38 5.38E-34 11 116660085 protein-coding gene
APOA4 4.06E-38 1.02E-33 11 116691417 protein-coding gene
APOC3 7.2E-38 1.81E-33 11 116700623 protein-coding gene
APOA1 1.23E-29 3.09E-25 11 116706468 protein-coding gene
APOA1-AS 1.53E-29 3.84E-25 11 116706832 non-coding RNA
SIK3 2.78E-29 6.99E-25 11 116714117 protein-coding gene
BUD13 5.57E-23 1.40E-18 11 116618885 protein-coding gene
PAFAH1B2 1.32E-18 3.32E-14 11 117014999 protein-coding gene
SIDT2 1.08E-16 2.71E-12 11 117049938 protein-coding gene
TAGLN 1.69E-16 4.25E-12 11 117070039 protein-coding gene
LOC100652768 1.85E-16 4.65E-12 11 117066328 unknown
PCSK7 3.59E-16 9.02E-12 11 117075786 protein-coding gene
KLKB1 5.86E-11 1.47E-06 4 187148671 protein-coding gene
RNF214 3.24E-10 8.14E-06 11 117103451 protein-coding gene
F11 9.03E-10 2.27E-05 4 187187117 protein-coding gene
CYP4V2 1.21E-09 3.04E-05 4 187112673 protein-coding gene
FLJ38576 3.35E-08 8.42E-04 4 187110185 unknown
Table 3. Look-up of lead apoA-IV SNPs in other consortia, providing
P-values
P-value of association with. . .
SNPs TG HDL-C eGFR
rs1729407 (APOA4) 0.96 7.1E-07 0.73
rs4253311 (KLKB1) 0.07 0.54 0.17
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with HDL-C (P¼ 7.11007). However, this SNP seems to be inde-
pendent from the lead SNP of the lipid-GWA within that gene
region (rs964184, reported gene APOA1, r2 with rs1729407< 0.1),
which had a P-value of 6.00E-48 in the GWAS on HDL-C and
7.0010224 in the GWAS on triglycerides (24). SNP rs964184 has
also been associated with coronary heart disease on a genome-
wide scale, an association possibly triggered by the strong asso-
ciation of rs964184 with triglyceride concentrations (42–44). In
our analysis, rs964184 was also associated with apoA-IV
(P¼ 0.0001). However, this is far away from genome-wide signifi-
cance. Altogether, it seems that, despite being within the
APOA5-A4-C3-A1 gene cluster, the SNPs associated with HDL-C
and triglycerides are statistically independent from the APOA4-
SNPs associated with apoA-IV concentrations.
We also performed a look-up to check whether the SNPs de-
tected in our apoA-IV GWAS study were associated with kidney
function, defined by eGFR using data from the CKDGen consor-
tium (45). This consortium was chosen because of the already
known association of apoA-IV with kidney function and chronic
kidney disease (13–16,46). However, none of the APOA4 and
KLKB1 lead SNPs showed significant associations with eGFR.
We further applied a look-up approach the other way
around: when we selected in total 142 unique SNPs that were re-
trieved from the kidney- and lipid-GWAS, no single SNP was as-
sociated with apoA-IV in our GWAS besides the aforementioned
SNP in APOA1 (TG and HDL-C). However, taken together as
weighted SNP-scores, the strongest associations with apoA-IV
could be found for the kidney-SNP-score and still significant as-
sociations for the triglycerides-SNP-score. These results poten-
tially support a possible causal effect of kidney function on
apoA-IV concentrations. This might also be true for a potential
causal effect of triglycerides on apoA-IV, but to a lesser extent.
So far, only few studies investigated the association between
apoA-IV and triglyceride levels, and the results have been in-
consistent: for example, no association could be found in the
EARS study (1261 controls and 629 cases) (23), whereas a study
conducted in 105 participants reported a significantly positive
association between apoA-IV and triglyceride levels (47) concen-
trations. This finding is contradictory to the direction of correla-
tion we found using a triglyceride-increasing SNP-score.
As part of the HDL particle, apoA-IV plays a role as a media-
tor in the reverse-cholesterol transport (48). Some epidemiologi-
cal studies also suggest an association of HDL-C with apoA-IV
(23). However, a causal role of HDL-C on apoA-IV could not be
shown with our data, but also not ruled out. In Hanniman et al.
(49), APOA4 knockout mice showed decreased HDL-C values,
whereas overexpression of APOA4 led to increase of HDL-C,
which suggests a causal role of apoA-IV on HDL-C.
Conclusion
Using data from five population-based studies and two addi-
tional replication studies, two independent SNPs located in or
next to the APOA4 gene and one SNP in KLKB1 gene were
significantly associated with apoA-IV levels. These two gene re-
gions alone can only explain a small fraction of the genome-
wide explained variance by SNPs which we estimated to be
roughly 30%. Therefore, a major part of apoA-IV variability is
likely to be regulated by non-genetic factors. Analyses of SNP-
scores explaining kidney function, HDL-C and triglyceride levels
indicate a potential causal effect of the primary kidney function
and by a lesser extent triglycerides on apoA-IV levels.
Methods
Study design
The genome-wide SNP association analysis on apoA-IV is based
on a two-stage design with a discovery stage and a replication
stage (Figure 1). Genome-wide SNP arrays were available for 5
studies of European ancestry (n¼ 13,813 in total). All indepen-
dent SNPs and missense variants with a P-value below 110 6
were taken forward to the replication stage. In addition, one
non-synonymous SNP from the APOA4 gene that did not fulfill
the P-value selection criteria was selected for replication (rs675),
since it has been widely studied before (18). Altogether, 8 SNPs
were then genotyped in both replication studies. Replication of
SNPs was achieved, if the following criteria were met: genome-
wide significance (P < 510 8) in the meta-analysis of all 7
studies within the discoveryþ replication stage (n¼ 16,080 in to-
tal), direction of effects in replication studies consistent with
the discovery stage and a false-discovery rate (FDR) (50) less
than 0.05 on the replication stage.
GWAS discovery stage: study population, genotyping
and imputation
Details on genotyping and imputation for each study can be
found in Supplementary Material, Table 2.
The CoLaus study is a single-centre, cross-sectional study
including 6,182 Caucasian subjects aged 35–75 years from the
city of Lausanne in Switzerland (51). From 5,435 participants, ge-
notypes were imputed using the software minimac (52) and
1000 Genomes (phase 1, version 3), resulting in over 7 million
SNPs after filtering. Full phenotype information as well as im-
puted genotypes are available for n¼ 3,996 participants.
For the NHLBI Family Heart Study (FamHS), 1,200 families
(6,000 individuals) were ascertained in 1992, half randomly
sampled, half selected because of an excess of coronary heart
disease (CHD) or risk factor abnormalities (53). Study partici-
pants belonging to the largest pedigrees were invited for a sec-
ond clinical exam (2002–2004). GWAS analysis was undertaken
for 4135 European American subjects using Illumina arrays. SNP
genotypes were subsequently imputed with the software MACH
(version1.0.16) (54) using 1000 genomes phase 1 version 3 (55) as
reference, leading to a total of 7.7 million SNPs after filtering.
Both imputed genotype data as well as phenotype information
was available for n¼ 1,712 participants.
Table 4. Association of weighted SNP-scores including susceptibility SNPs for kidney function, HDL cholesterol and triglycerides (TG) with log-
transformed apoA-IV levels (age-and sex-adjusted) in the combined KORAF3 and F4 dataset using a mixed effects model.
Weighted SNP scores beta se P-value Explained variance in %
Kidney function SNP-score (53 SNPs) 0.4068 0.1008 5.50E-05 0.33%
HDL cholesterol SNP-score (70 SNPs) 0.0246 0.0130 0.0575 0.06%
Triglycerides SNP-score (38 SNPs) 0.0430 0.0161 0.0078 0.12%
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The KORA F3 study, conducted in the years 2004/05, is a
population-based sample from the general population living in
the region of Augsburg, Southern Germany, which has evolved
from the WHO MONICA study (Monitoring of Trends and
Determinants of Cardiovascular Disease). Genome-wide data
are available for all participants (n¼ 3,075 with complete pheno-
type information) based on llumina Omni 2.5/Illumina Omni
Express. The KORA F4 survey is an independent non-
overlapping sample drawn from the same population in the
years 2006/08 (n¼ 2,926 with complete phenotype information).
Genome-wide data are available for all participants in the KORA
F4 study (Affymetrix Axiom) (40,56). Both genome-wide geno-
type data have been imputed with the software IMPUTE using
1000 Genomes phase 1, version 3 (55). After quality control and
filtering, about 8.5 M SNPs are available for analyses in both
KORA F3 and F4.
The Cardiovascular Risk in Young Finns Study (YFS) is a pro-
spective multicenter study from Finland initiated in 1980
(Baseline age 3–18 years) with several follow-ups over 30 years
to investigate childhood risk factors for cardiometabolic out-
comes (57). For 2443 participants from the 2001 follow-up (ages
24-39 years), high throughput genome wide SNP genotyping us-
ing the genome wide Illumina 670K SNP chip was performed at
the Wellcome Trust Sanger Centre. Imputation was performed
using IMPUTE and the 1000 Genomes Project March 2012 version
(phase 1, version 3) as reference, leading to a total of 8.5 million
imputed genotypes after filtering. Full phenotype information
as well as imputed genotypes is available for n¼ 2,104
participants.
Replication stage: study population and de-novo
genotyping
The Bruneck study is a prospective population-based survey de-
signed to investigate the epidemiology and pathogenesis of ath-
erosclerosis (58,59). The study population was recruited in 1990
as a sex- and age-stratified random sample of all inhabitants of
Bruneck, Italy. The attendance rate was 93.6% with complete
data in 919 subjects. An intensive phenotyping was done and
follow-up data are available for a period of 25 years.
The SAPHIR study (Salzburg Atherosclerosis Prevention
Program in subjects at High Individual Risk) is an observational
study conducted in the years 1999–2002 involving 1,770 unre-
lated subjects from a healthy working population. Study partici-
pants were recruited by health-screening programs in
companies in and around the Austrian city of Salzburg (60). Full
phenotype and genotype information is available for n¼ 1,454
participants.
In both studies, de-novo genotyping was performed in a
multiplex approach using the SEQUENOM MassArray platform
and iPLEX Gold chemistry. Full phenotype and genotype infor-
mation is available for n¼ 802 participants.
Measurement of apoA-IV
For all participating studies, quantification of plasma apoA-IV
was done in the same laboratory (Division of Genetic
Epidemiology, Medical University of Innsbruck, Austria). It was
based on a double-antibody enzyme-linked immunosorbent as-
say using an affinity-purified polyclonal rabbit anti-human
apoA-IV antibody for coating and the same antibody coupled to
horseradish peroxidase for detection. Plasma with a known
concentration of apoA-IV was used as the calibration standard
(61). Four control sera with different concentrations were run on
each plate in double measurements for control purposes
throughout the entire project. The intra- and interassay coeffi-
cients of variation were 2.7% and 6.0%, respectively (61).
Statistical methods
GWAS analysis of single studies & discovery stage meta-analysis
An overview of the quality control and meta-analysis workflow
in the discovery stage is given in Supplementary Material,
Figure 1. Due to the skewed distribution of apoA-IV concentra-
tions, log-transformation of values was performed in all studies,
resulting in nearly normal distributions (Supplementary
Material, Figure 2). In each study, each SNP was associated with
log-transformed apoA-IV concentrations in an additive genetic
model using linear regression, adjusted for age and sex.
Additionally, linear regression was performed on the untrans-
formed apoA-IV levels to obtain interpretable effect estimates.
Since women have slightly lower apoA-IV levels than men,
gender-stratified models have also been applied in all studies
(62). Genome-wide analysis in the FamHS study was performed
using a linear mixed model accounting for familial dependen-
cies described by a pedigree-based kinship matrix.
Quality control and filtering of SNPs was performed centrally
and standardized by the Innsbruck study group using EasyQC
(63). SNPs were only included in the analysis if they fulfilled the
following criteria: imputation quality0.4 (e.g. IMPUTE info),
minor allele frequency1% and a P-value of the HWE-
test 11006. Additional analyses for quality control were ap-
plied on the already filtered datasets, which included a P-Z-plot
(63) and calculation of genomic inflation factor k. The P-Z-plot
compares the reported P-values from each study with the P-val-
ues calculated from Z-statistics derived from the reported beta
coefficient and standard error.
For the meta-analysis over all GWAS studies, METASOFT (64)
was used for all imputed SNPs that met imputation and quality
control criteria. SNPs were only included in the meta-analysis if
they were available in 3 or more studies. Based on the heteroge-
neity between studies for each SNP, a fixed effects (FE) or opti-
mized random effects model (RE) as proposed by (64), was used
as implemented in METASOFT. The test statistic for this opti-
mized RE model is partitioned into a mean effects and heteroge-
neity part. To give higher weights to the mean effects, this RE
model was only used when the test statistic for the mean effects
part was higher than the heterogeneity part and if the test for
heterogeneity was significant (p value of Q statistic< 0.1 &
I250). The test statistics were corrected for genomic inflation
in both the GWAS analysis stage and meta-analysis stage.
Based on the gender-stratified analyses, a t-test on effect differ-
ences between men and women was performed (62). All re-
gional plots presenting the P-values and LD between SNPs in
predefined genomic regions were done using LocusZoom (65).
SNP selection for replication
To detect independently associated SNPs, a conditional step-
wise analysis was performed using the program GCTA (version
1.24.7 (66)). For each locus with at least one P-value< 106, the
SNP with the lowest P-value on the discovery stage was taken
as the lead SNP. All SNPs within a regionþ/- 500 kB surrounding
the lead SNP were included in the conditional analysis. GCTA
uses the summary-level statistics of the meta-analysis plus one
reference population for LD calculation. As reference
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population, a combined genotype dataset of KORA F3 and KORA
F4 was used (n¼ 6,001). By default, the lead SNP is included in
the model. Then, all SNPs in the included gene region are tested
for association in addition to the already included SNPs. Finally,
all SNPs within a gene region with a P-value of< 10  6 in the
conditional analysis were taken forward for replication.
Furthermore, all missense mutations with P-values of<106
were selected for replication, irrespective of possible LD with al-
ready selected SNPs.
Two-stage meta-analysis
All genotyped SNPs in the replication phase were meta-
analyzed in both replication studies separately as well as in a
combined analysis of all GWAS and replication-stage studies.
Again, METASOFT (64) was used in the same way as in the first
stage meta-analysis.
Gene-based test and pathway analysis
In addition to the analysis of single SNP effects, a gene-based
scan and a pathway analysis were performed using KGG ver-
sion 3.5 (67). Gene regions were defined as the gene6 20 kb ac-
cording to the RefGene database. Using this definition, 66.35%
of the available SNPs were included in the analysis. For the
gene-based analysis, the extended Simes test (GATES) was
used as implemented in KGG (68). To adjust for multiple test-
ing, the Bonferroni-method was applied on the number of
tested genes. To calculate LD between the SNPs, the 1000G
Phase 1 v3 Reference was used. All pathways that are avail-
able in the C2 curated gene set from GSEA (http://software.
broadinstitute.org/gsea/msigdb/) were included in the path-
way analysis. To test for enrichment of each pathway with
significant genes, a hypergeometric test as implemented in
KGG was used (69). To adjust for multiple testing, the
Bonferroni-method was applied on the number of pathways
tested.
Variance explained
The percentage of explained variance for the SNPs that were
taken forward for replication was calculated in the SAPHIR
study (n¼ 1,465) - as an independent replication cohort - as well
as in a combined dataset of both KORA studies (n¼ 6,001). The
combined KORA dataset was also used to get an estimate of the
proportion of phenotypic variance explained by the regression
on additively coded SNPs for a) all SNPs within the APOA4 and
KLKB1 gene regions, defined as the lead SNPsþ/- 500 kB, as in
the conditional analysis and b) all available genome-wide im-
puted SNPs. The latter has been denoted as the genomic herita-
bility (70). Hence, this genomic heritability includes solely the
variance attributable to the measured SNP effects. For these
analyses, the software GCTA version 1.24.7 was used (66). In the
FamHS study, an estimate of the proportion of the additive
(polygenic) variance on the phenotypic variance, the narrow-
sense heritability h2, was obtained using GenABEL’s polygenic
function, taking the kinship matrix into account. This narrow-
sense heritability thus also includes the variance explained by
not measured SNPs and other variants (e.g. copy-number-
variations). All estimates for the explained variance and herita-
bility refer to log-transformed values of apoA-IV.
SNP look-up
We performed a look-up of our replicated SNPs in downloadable
GWA meta-analysis results on kidney function (defined by
eGFR) (71), HDL-C and triglycerides (24). We further looked up
lead SNPs identified in these consortia in our apoA-IV GWA
meta-analysis. 53 SNPs associated with kidney function, defined
by eGFR, were derived from the CKDGen-GWA meta-analysis
and 70 SNPs with HDL-C and 38 with triglycerides from the
GLGC-GWA meta-analysis. For these SNPs, their respective P-
values from the log-transformed analysis on apoA-IV levels on
the discovery stage were looked up. Altogether, 143 unique
SNPs were included in this analysis, some of them involved in
more than one phenotype (especially for HDL-C and triglycer-
ides). Therefore, results are declared significant, when the P-
value is lower than 0.05/143¼ 0.00035. Since the effect of single
SNPs (and therefore the statistical power) is assumed to be low,
we also used the imputed genotypes in both KORA studies to
create SNP-scores. Weighting and direction of effects were
based on the original publication where the SNPs were derived
from. All SNPs were scaled in such a way that they are pheno-
type and/or risk increasing and weighted by the beta-estimate
derived from the respective original study. These weighted ge-
notype scores were then summed up to derive a genetic risk
score for each of the phenotypes studied. For these analyses, a
combined dataset of KORAF3 and KORAF4 was used (n¼ 6,001).
A mixed effects model was performed for this analysis with the
study included as a random effects variable. Since three SNP-
scores were evaluated, the significance threshold was set to
0.05/3¼ 0.0167 for these analyses.
Bioinformatic analysis
Bioinformatic analysis of intergenic variants using ENCODE
data was carried out as described before (72). Analysis of the
coding variants was performed using tools Polyphen-2 (73), SIFT
(74) and MutPred (75). Pairwise LDs were calculated using SNiPA
(76) (http://snipa.helmholtz-muenchen.de) using the European
1000 Genomes Phase 3, v5 dataset.
Supplementary Material
Supplementary Material is available at HMG Online.
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